Grundläggande statistik
| CIK | 1002811 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kensey Nash Corp
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| February 11, 2013 |
KNSY / Kensey Nash Corp / VANGUARD GROUP INC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3 )* Name of issuer: Kensey Nash Corp Title of Class of Securities: Common Stock CUSIP Number: 490057106 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: (X) |
|
| July 10, 2012 |
KNSY / Kensey Nash Corp / BROWN CAPITAL MANAGEMENT LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 10)* Kensey Nash Corporation (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 490057106 (CUSIP Number) June 30, 2012 (Date of E |
|
| July 2, 2012 |
Form 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-34388 Kensey Nash Corporation (Exact name of registrant as spec |
|
| June 26, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 26, 2012 Registration No. 333-04093 Registration No. 333-22993 Registration No. 333-71050 Registration No. 333-117354 Registration No. 333-139494 Registration No. 333-148090 Registration No. 333-156427 Registration No. 333-171317 Registration No. 333-178709 UNITED STATES SECURITIES AND EXCHANGE |
|
| June 26, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 26, 2012 Registration No. 333-04093 Registration No. 333-22993 Registration No. 333-71050 Registration No. 333-117354 Registration No. 333-139494 Registration No. 333-148090 Registration No. 333-156427 Registration No. 333-171317 Registration No. 333-178709 UNITED STATES SECURITIES AND EXCHANGE |
|
| June 26, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 26, 2012 Registration No. 333-04093 Registration No. 333-22993 Registration No. 333-71050 Registration No. 333-117354 Registration No. 333-139494 Registration No. 333-148090 Registration No. 333-156427 Registration No. 333-171317 Registration No. 333-178709 UNITED STATES SECURITIES AND EXCHANGE |
|
| June 26, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 26, 2012 Registration No. 333-04093 Registration No. 333-22993 Registration No. 333-71050 Registration No. 333-117354 Registration No. 333-139494 Registration No. 333-148090 Registration No. 333-156427 Registration No. 333-171317 Registration No. 333-178709 UNITED STATES SECURITIES AND EXCHANGE |
|
| June 26, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As filed with the Securities and Exchange Commission on June 26, 2012 Registration No. |
|
| June 26, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 26, 2012 Registration No. 333-04093 Registration No. 333-22993 Registration No. 333-71050 Registration No. 333-117354 Registration No. 333-139494 Registration No. 333-148090 Registration No. 333-156427 Registration No. 333-171317 Registration No. 333-178709 UNITED STATES SECURITIES AND EXCHANGE |
|
| June 26, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 26, 2012 Registration No. 333-04093 Registration No. 333-22993 Registration No. 333-71050 Registration No. 333-117354 Registration No. 333-139494 Registration No. 333-148090 Registration No. 333-156427 Registration No. 333-171317 Registration No. 333-178709 UNITED STATES SECURITIES AND EXCHANGE |
|
| June 26, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 26, 2012 Registration No. 333-04093 Registration No. 333-22993 Registration No. 333-71050 Registration No. 333-117354 Registration No. 333-139494 Registration No. 333-148090 Registration No. 333-156427 Registration No. 333-171317 Registration No. 333-178709 UNITED STATES SECURITIES AND EXCHANGE |
|
| June 26, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on June 26, 2012 Registration No. 333-04093 Registration No. 333-22993 Registration No. 333-71050 Registration No. 333-117354 Registration No. 333-139494 Registration No. 333-148090 Registration No. 333-156427 Registration No. 333-171317 Registration No. 333-178709 UNITED STATES SECURITIES AND EXCHANGE |
|
| June 25, 2012 |
BYLAWS KENSEY NASH CORPORATION (a Delaware corporation) ARTICLE I Exhibit 3.2 BYLAWS OF KENSEY NASH CORPORATION (a Delaware corporation) ARTICLE I STOCKHOLDERS 1.1 CERTIFICATES REPRESENTING STOCK. Certificates representing stock in the corporation shall be signed by, or in the name of, the corporation by the Chairperson or Vice-Chairperson of the Board of Directors, if any, or by the President or a Vice-President and by the Treasurer or an Assistant Treasurer or |
|
| June 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2012 Kensey Nash Corporation (Exact name of registrant as specified in its charter) Delaware 001-34388 36-3316412 (State or other Jurisdiction of Incorporation) (Commission F |
|
| June 25, 2012 |
Exhibit 99.1 Press Release Heerlen, 25 June 2012 DSM, Corporate Communications e-mail: [email protected] www.dsm.com 18E DSM completes acquisition of Kensey Nash and strengthens its biomedical business Royal DSM, the global Life Sciences and Materials Sciences company, today announces that it has successfully completed the acquisition of Kensey Nash, through the merger of its subsidiary Biom |
|
| June 25, 2012 |
KNSY / Kensey Nash Corp / Royal DSM N.V. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 20, 2012 |
KNSY / Kensey Nash Corp / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Kensey Nash Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 490057106 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Re |
|
| June 19, 2012 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 19, 2012 |
- AMENDMENT NO. 2 TO SCHEDULE 14D-9 Amendment No. 2 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) KENSEY NASH CORPORATION (Name of Subject Company) KENSEY NASH CORPORATION (Name of Person Filing Statement) Common Stock, par value $0.001 per sha |
|
| June 19, 2012 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(5)(I) Press Release Heerlen, 19 June 2012 DSM, Corporate Communications e-mail: media. |
|
| June 12, 2012 |
KNSY / Kensey Nash Corp / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Kensey Nash Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 490057106 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Re |
|
| June 7, 2012 |
KNSY / Kensey Nash Corp / BLAIR WILLIAM & CO/IL - AMENDMENT TO SCHEDULE 13G Passive Investment SC 13G/A 1 v315476sc13ga.htm AMENDMENT TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 6)* Kensey Nash Corporation (Name of Issuer) Common (Title of Class of Securities) 49005 |
|
| June 6, 2012 |
- AMENDMENT NO. 1 TO SCHEDULE 14D-9 Amendment No. 1 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) KENSEY NASH CORPORATION (Name of Subject Company) KENSEY NASH CORPORATION (Name of Person Filing Statement) Common Stock, par value $0.001 per sha |
|
| June 6, 2012 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 6, 2012 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(5)(H) Press Release Heerlen, 6 June 2012 DSM, Corporate Communications e-mail: media. |
|
| May 23, 2012 |
KNSY / Kensey Nash Corp / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Kensey Nash Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 490057106 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and |
|
| May 21, 2012 |
Exhibit (a)(2) May 21, 2012 Dear Stockholder: As we publicly announced on May 3, 2012, Kensey Nash Corporation (“Kensey Nash”) has entered into an Agreement and Plan of Merger, dated as of May 2, 2012 (the “Merger Agreement”), with Koninklijke DSM N. |
|
| May 21, 2012 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(B) THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION LETTER OF TRANSMITTAL To Tender Shares of Common Stock (including the associated Series A Junior Participating Preferred Stock Purchase Rights) of Kensey Nash Corporation at $38. |
|
| May 21, 2012 |
Exhibit (a)(5)(G) Press Release DSM, Corporate Communications Heerlen, 21 May 2012 e-mail: media. |
|
| May 21, 2012 |
CONFIDENTIALITY AND STANDSTILL AGREEMENT Exhibit 99.(d)(2) November 14, 2011 Royal DSM N.V. P.O. Box 6500 6401 JH Heerlen The Netherlands Attention: Hein Schreuder CONFIDENTIALITY AND STANDSTILL AGREEMENT Dear Hein: Jefferies & Company, Inc. (“Jefferies”) has been engaged by Kensey Nash Corporation (the “Company”) to assist and advise the Company in connection with a possible transaction (a “Transaction”) with Royal DSM N.V. and/or one o |
|
| May 21, 2012 |
Exhibit (a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock (including the associated Series A Junior Participating Preferred Stock Purchase Rights) of Kensey Nash Corporation at $38. |
|
| May 21, 2012 |
Exhibit (a)(5)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| May 21, 2012 |
EX-99.(A)(1)(D) 5 a2209672zex-99a1d.htm EX-99.(A)(1)(D) QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock (including the associated Series A Junior Participating Preferred Stock Purchase Rights) of Kensey Nash Corporation at $38.50 Net Per Share by Biomedical Acquisition Corporation an indirect whol |
|
| May 21, 2012 |
SCHEDULE 14D-9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 21, 2012 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 21, 2012 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(C) Notice of Guaranteed Delivery for Offer to Purchase for Cash All Outstanding Shares of Common Stock (including the associated Series A Junior Participating Preferred Stock Purchase Rights) of Kensey Nash Corporation at $38. |
|
| May 21, 2012 |
EX-99.(A)(1)(A) 2 a2209672zex-99a1a.htm EX-99.(A)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock (including the associated Series A Junior Participating Preferred Stock Purchase Rights) of Kensey Nash Corporation at $38.50 Net Per Share by Biomedical Acquisition Corporation an indirect wholly-owned subsidiary of Koninklijke DSM N.V. THE |
|
| May 10, 2012 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 10, 2012 |
Schedule 14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 Kensey Nash Corporation (Name of Subject Company) Kensey Nash Corporation (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 4 |
|
| May 8, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 Kensey Nash Corporation (Name of Subject Company) Kensey Nash Corporation (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 490057106 (CUSIP |
|
| May 3, 2012 |
EX-99.(A)(5)(E) 6 dsm-exa5e.htm |
|
| May 3, 2012 |
Transcript of DSM Video Presentation titled “DSM and Kensey Nash: a leading biomedical business”, May 3, 2012 Additional Information The tender offer described in this news release has not yet been commenced. |
|
| May 3, 2012 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among KONINKLIJKE DSM N.V., BIOMEDICAL ACQUISITION CORPORATION and KENSEY NASH CORPORATION Dated as of May 2, 2012 TABLE OF CONTENTS Page ARTICLE 1 THE OFFER AND THE MERGER 2 Section 1.1 The Offer 2 Section 1.2 Company Actions 4 Section 1.3 The Merger 5 Section 1.4 Effects of the Merger 6 Section 1.5 Closing 6 Section 1.6 Consummation of the Merger 6 Sectio |
|
| May 3, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KENSEY NASH CORPORATION (Name of Subject Company (Issuer)) KONINKLIJKE DSM N.V. BIOMEDICAL ACQUISITION CORPORATION (Names of Filing Persons (Offerors)) Common Stock, $0.001 Par Value Per Share (Title of Class of Securit |
|
| May 3, 2012 |
KENSEY NASH REPORTS THIRD QUARTER FISCAL YEAR 2012 FINANCIAL RESULTS EX-99.1 4 d343128dex991.htm PRESS RELEASE ANNOUNCING ITS OPERATING RESULTS Exhibit 99.1 CONTACT: Joseph W. Kaufmann President and Chief Executive Officer (484) 713-2100 KENSEY NASH REPORTS THIRD QUARTER FISCAL YEAR 2012 FINANCIAL RESULTS EXTON, PA, MAY 3, 2012 — Kensey Nash Corporation (NASDAQ: KNSY), a medical device company primarily focused on regenerative medicine for a wide range of medical p |
|
| May 3, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2012 Kensey Nash Corporation (Exact name of registrant as specified in its charter) Delaware 001-34388 36-3316412 (State or other Jurisdiction of Incorporation) (Commi |
|
| May 3, 2012 |
TRANSCRIPT MEDIACALL Mr. Feike Sijbesma, CEO/Chairman of DSM Managing Board Mr. Rob van Leen, Chief Innovation Officer DSM Mr. Rolf-Dieter Schwalb, CFO/Member of DSM Managing Board Mr. Herman Betten, Corporate Communications DSM Mr. Betten: Ladies and gentlemen, welcome to this DSM conference call and thank you for joining us on such short notice. Today we are here to announce the signing of a def |
|
| May 3, 2012 |
Form 8-A/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Kensey Nash Corporation (Exact name of registrant as specified in its charter) Delaware 36-3316412 (State of incorporation or organization) (I.R.S. Employer Identif |
|
| May 3, 2012 |
TRANSCRIPT ANALYST CALL Mr. Feike Sijbesma, CEO/Chairman of DSM Managing Board Mr. Rob van Leen, Chief Innovation Officer DSM Mr. Rolf-Dieter Schwalb, CFO/Member of DSM Managing Board Mr. Hans Vossen, Director Investor Relations DSM Mr. Vossen: Ladies and gentlemen, welcome to this DSM conference call and thank you for joining us on such short notice. Today we are here to announce the signing of a |
|
| May 3, 2012 |
Press Release Heerlen, 3 May 2012 DSM, Corporate Communications e-mail: [email protected] www.dsm.com DSM agrees to acquire Kensey Nash to strengthen its biomedical business • DSM (NYSE Euronext: DSM KON) to offer USD 38.50 for each share of Kensey Nash (NASDAQ: KNSY) in an all-cash transaction through a tender offer • Total enterprise value of approximately USD 360 million (about €275 milli |
|
| May 3, 2012 |
SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 Kensey Nash Corporation (Name of Subject Company) Kensey Nash Corporation (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 4 |
|
| May 3, 2012 |
Exhibit 4.1 AMENDMENT TO RIGHTS AGREEMENT THIS AMENDMENT TO RIGHTS AGREEMENT (this “Amendment”) is executed as of May 2, 2012 by and among Kensey Nash Corporation, a Delaware corporation (the “Company”), and Computershare Trust Company, N.A., a federally chartered trust company (the “Rights Agent”), amending the Rights Agreement, dated as of June 18, 2009, between the Company and the Rights Agent |
|
| May 3, 2012 |
Exhibit 99.2 CONTACT: Joseph W. Kaufmann President and Chief Executive Officer (484) 713-2100 KENSEY NASH AGREES TO BE ACQUIRED BY DSM FOR $38.50 PER SHARE IN CASH DSM will commence all-cash tender offer in May Tender Offer expected to be completed by June 30, 2012 EXTON, Pa., May 3, 2012 — Kensey Nash Corporation (Nasdaq: KNSY), today announced that it has entered into a definitive agreement with |
|
| April 25, 2012 |
Submission of Matters to a Vote of Security Holders - KENSEY NASH CORP--AMENDMENT NO. 1 TO FORM 8-K Kensey Nash Corp-Amendment No. 1 to Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 to CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2011 Kensey Nash Corporation (Exact name of registrant as specified in its charter) Delaware 001-34388 36 |
|
| March 19, 2012 |
Exhibit 99.1 CONTACT: Joseph W. Kaufmann President and Chief Executive Officer (484) 713-2100 KENSEY NASH ANNOUNCES MEDIATED SETTLEMENT WITH ST. JUDE MEDICAL IN ANGIO-SEAL LICENSE DISPUTES AND 5 YEAR EXTENSION AND EXPANSION OF COLLAGEN SUPPLY AGREEMENT EXTON, PA, March 16, 2012 – Kensey Nash Corporation (NASDAQ: KNSY) today announced that the Company has entered into a settlement agreement with St |
|
| March 19, 2012 |
EX-10.1 2 d317280dex101.htm CONFIDENTIAL SETTLEMENT AGREEMENT Exhibit 10.1 SETTLEMENT AGREEMENT *** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST UNDER 17 C.F.R SECTIONS 24-b-2, 200.80 (B)(4) AND 230.406. 1. INTRODUCTION 1.1 This Settlement Agreement (“the Agreement”) is ma |
|
| March 19, 2012 |
Kensey Nash Corporation - Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 13, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2012 Kensey Nash Corporation (Exact name of registrant as specified in its charter) Delaware 001-34388 36-3316412 (State or other jurisdiction of incorporation or o |
|
| March 13, 2012 |
KENSEY NASH CORPORATION DECLARES A QUARTERLY DIVIDEND OF $0.25 PER SHARE Press Release Exhibit 99.1 CONTACT: Joseph W. Kaufmann President and Chief Executive Officer (484) 713-2100 KENSEY NASH CORPORATION DECLARES A QUARTERLY DIVIDEND OF $0.25 PER SHARE EXTON, PENNSYLVANIA, March 13, 2012 — The board of directors of Kensey Nash Corporation (Nasdaq: KNSY) announced today that the board has declared a cash dividend of $0.25 per share of the Company’s common stock, payabl |
|
| February 13, 2012 |
KNSY / Kensey Nash Corp / BROWN CAPITAL MANAGEMENT LLC - KENSEY NASH CORPORATION Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 9)* Kensey Nash Corporation (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 490057106 (CUSIP Number) December 31, 2011 (Date o |
|
| February 9, 2012 |
KNSY / Kensey Nash Corp / VANGUARD GROUP INC Passive Investment kenseynashcorp.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.:2 )* Name of issuer: Kensey Nash Corp Title of Class of Securities: Common Stock CUSIP Number: 490057106 Date of Event Which Requires Filing of this Statement: December 31, 2011 Check the appropriate box to de |
|
| February 9, 2012 |
Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: December 31, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number: 001-34388 Kensey |
|
| February 2, 2012 |
Kensey Nash Reports Second Quarter Fiscal Year 2012 Financial Results Kensey Nash Reports Second Quarter Fiscal Year 2012 Financial Results EXTON, Pa., Feb. 2, 2012 /PRNewswire/ - Kensey Nash Corporation (NASDAQ: KNSY), a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its second fiscal quarter ended December 31, 2011. Second Quarter Snapshot and Recent Developments Adjusted dil |
|
| February 2, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2012 Kensey Nash Corporation (Exact name of registrant as specified in its charter) Delaware 001-34388 36-3316412 (State or other jurisdiction of incorporation or organiza |
|
| January 30, 2012 |
KNSY / Kensey Nash Corp / BLAIR WILLIAM & CO/IL - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 05)* KENSEY NASH CORP. (Name of Issuer) Common (Title of Class of Securities) 490057106 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 3, 2012 |
Press Release Exhibit 99.1 CONTACT: Joseph W. Kaufmann President and Chief Executive Officer (484) 713-2100 KENSEY NASH CORPORATION ADOPTS CASH DIVIDEND POLICY; DECLARES INITIAL QUARTERLY DIVIDEND OF $0.25 PER SHARE EXTON, PENNSYLVANIA, January 3, 2012 — The board of directors of Kensey Nash Corporation (Nasdaq: KNSY) announced today that the board has declared a cash dividend of $0.25 per share o |
|
| January 3, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 3, 2012 Kensey Nash Corporation (Exact name of registrant as specified in its charter) Delaware 001-34388 36-3316412 (State or other jurisdiction of incorporation or |
